** Animal diagnostics maker IDEXX Laboratories' IDXX.O shares down 1.2% at $406.41

** BofA Global Research cuts PT to $475 from $535 on vet visit declines

** The new PT represents a 30% upside to the stock's last close

** "IDXX's direct leverage to clinic visit volumes creates a tough setup given the weak readings through Q1 and April so far" - BofA

** Brokerage says vet visit trends "leave a little room for upside revisions"

** IDXX expects about a 2% decline in clinical visits for 2025 - co said on a Q4 conference call

** Eight of 14 brokerages rate the stock "buy" or higher, six "hold"; their median PT is $502.13 - LSEG

** Including session's move, IDXX down 1.5% YTD

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))